Arena BioWorks closes less than two years after $500m launch

Arena BioWorks, a privately funded biomedical research institute that aimed to overhaul the traditional drug discovery model, has closed its doors less than two years after its $500 million launch. The decision follows what its founding investor group called “dramatic changes” in biotech market conditions, with no clear recovery in sight.

The Boston-based board said the unanimous vote to dissolve Arena reflected persistent policy uncertainty and weak funding. Staff will receive severance and benefits coverage, while the company’s scientists plan to continue advancing the most promising medicines in oncology, immune disorders and brain health that originated at the institute.

Founded in 2024 by Stuart Schreiber, Steve Pagliuca and Tom Cahill, Arena set out to fund early ideas privately through to human readiness. The company opened a research centre in Cambridge, Massachusetts, combining academic discovery, translational research and company creation in one space. Its work spanned neurology, oncology, immunology and ageing, supported by artificial intelligence and mechanistic biology.